iiinova — where your digital self keeps evolving

Reposted by The Institute of Cancer Research

Cancer Grand Challenges @cancergrand.bsky.social · 04/09/2026

Congratulations to our poster prize winners at our Cancer Grand Challenges Conference: Spatial biology! 🎉 Soham Mandal, @icr.ac.uk, won the @natrevcancer.nature.com prize. Emine Kazanc, @icr.ac.uk, won the @aacrjournals.bsky.social #CancerDiscovery prize. A huge thank you to both journals.

022

The Institute of Cancer Research @icr.ac.uk · 11/09/2026

What have been the biggest breakthroughs in cancer research over the past 25 years? Professor Paul Workman OBE shares his perspective in Nature Reviews Cancer's special anniversary Viewpoint on the path from cancer genomics to precision medicine. Read the article ⤵️ www.nature.com/articles/s41...

022

The Institute of Cancer Research @icr.ac.uk · 08/09/2026

Published in The Lancet Oncology, the study found that around 69 per cent of patients were still alive after six years. The findings also highlight the importance of advanced molecular testing to identify patients at greatest risk.

101

The Institute of Cancer Research @icr.ac.uk · 08/09/2026

New results from the UK-led OPTIMUM (MUKnine) trial show that patients with high-risk multiple #myeloma can live significantly longer when treatment is tailored to their disease.

100

Reposted by The Institute of Cancer Research

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 24/08/2026

How do cancers regulate endoplasmic reticulum pH and stress? We show that the Golgi anion channel GPR89 plays a key role by translocating to the ER. GPR89 enhances mammary tumorigenesis and targeting GPR89 inhibits mammary cancers. Work led by the amazing Rico Ferro www.nature.com/articles/s41...

nature.com

The anion channel GPR89 is a tumor-specific dependency in breast cancer - Nature Communications

Oncogene-driven endoplasmic reticulum (ER) stress is common in cancer. Here, authors show breast cancers extend Golgi anion channel GPR89 to the ER to mitigate this stress, creating a potentially targ...

121

Reposted by The Institute of Cancer Research

Christian Zierhut @zierlab.bsky.social · 21/08/2026

Supremely excited to share our new paper in @natcellbio.nature.com With an updated genetic cGAMP reporter, we reveal that cGAS activation by DNA damage is a rare event, and that cGAS enrichment on intracellular structures cannot be taken as evidence of activation. www.nature.com/articles/s41...

nature.com

A versatile cGAMP reporter reveals principles of cGAS activation by DNA damage and chromosome instability - Nature Cell Biology

Lebrec et al. present a FRET-based cGAS reporter and show that cGAS activation by genotoxic stress is rare and uncoupled from micronuclei. The study implicates R-loop structures and subtypes of chroma...

97130

The Institute of Cancer Research @icr.ac.uk · 14/08/2026

BREAKING 🚨: A new drug target has been discovered for an aggressive #BloodCancer. 🎥 Hear more from first author of the study, ICR's Dr Christopher Mapperley, Postdoctoral Fellow.

151

Reposted by The Institute of Cancer Research

Ferran Cardoso @fercr.bsky.social · 07/08/2026

Very excited to announce we are looking for a software engineer to support our work developing digital pathology applications at the Integrated Pathology Unit! Check out the link below and do not hesitate to reach out if you have any questions. @icr.ac.uk #hiring jobs.icr.ac.uk/vacancies/15...

jobs.icr.ac.uk

Software Engineer in Sutton | The Institute of Cancer Research

View details and apply for this Software Engineer vacancy in Sutton. Salary : Salary range: £57,190 - £64,000 per annum. Commencement on the salary range is subject to comparable skills and ...

012

Reposted by The Institute of Cancer Research

Cancer Research UK Cambridge Centre @crukcamcentre.bsky.social · 04/08/2026

Using a risk assessment tool researchers at @cam.ac.uk and @icr.ac.uk have found that NICE referral criteria miss up to 95% of women under 50 who go on to develop breast cancer within 10 years. 🔗 zurl.co/6NNxS @cancerresearchuk.org @breastcancernow.bsky.social

043

Reposted by The Institute of Cancer Research

Basil Greber @bjgreber.bsky.social · 24/07/2026

Happy that our most recent paper on nucleotide excision repair mechanisms has now been published in Science Advances. This project was led by @natalia-mg.bsky.social and @callumhaste.bsky.social and focused on visualising early steps of the NER process by #cryoEM. www.science.org/doi/10.1126/...

science.org

Visualization of stepwise derepression of TFIIH in global genome nucleotide excision repair

Cryogenic electron microscopy captures nucleotide excision repair complexes assembling on damaged DNA templates.

67318

The Institute of Cancer Research @icr.ac.uk · 17/07/2026

Paul shares a cartoon by Aaron Bacall which shows a patient approaching the pharmacist behind a well-stocked counter and announcing “Here’s my DNA sequence” in the expectation of receiving their personalised medications. As the blog details, to what extent have we moved towards that?

100

The Institute of Cancer Research @icr.ac.uk · 17/07/2026

Professor Paul Workman reflects on this milestone, assessing the great progress made in converting knowledge of the human genome into personalised medicines – what he describes as “drugging the cancer genome”.

100

The Institute of Cancer Research @icr.ac.uk · 17/07/2026

🧬 25 years ago, the first draft of the human genome was published, a momentous scientific achievement opening up huge potential for drug discovery. On its anniversary, how far have we come?

100

The Institute of Cancer Research @icr.ac.uk · 10/07/2026

ICR's Professor Gail ter Haar, Professor of Therapeutic Ultrasound said: “It is rewarding to see high-intensity focused ultrasound reaching this stage. We have developed the technology into use in patients, designing the clinical protocols that have led us to this point today.”

000

The Institute of Cancer Research @icr.ac.uk · 10/07/2026

ICR scientists led its development, ensuring that the technology is safe for use in patients. Now, our researchers have supported @imperialcollegeldn.bsky.social and Imperial College Healthcare NHS Trust to apply the technology to twin-twin transfusion syndrome.

100

The Institute of Cancer Research @icr.ac.uk · 10/07/2026

🖥️ An ultrasound technology pioneered at the ICR to treat tumours without the need for surgery has successfully been adapted and used to treat a serious pregnancy condition. High intensity focused ultrasound (HIFU) uses targeted sound waves to heat and destroy cells inside the body.

100

The Institute of Cancer Research @icr.ac.uk · 08/07/2026

His work is helping researchers identify why some cancers resist treatment, predict which therapies are most likely to benefit individual patients and bring us closer to a future where bowel cancer is more preventable, predictable and treatable.

100

The Institute of Cancer Research @icr.ac.uk · 08/07/2026

📰 In our latest feature, ICR's Professor Anguraj Sadanandam explains how his pioneering research is combining #AI, advanced diagnostics and innovative preclinical models to better understand #BowelCancer and help develop more personalised treatments.

100

The Institute of Cancer Research @icr.ac.uk · 18/06/2026

📢 New @fda.gov approval for #capivasertib in advanced #ProstateCancer. The drug, made possible by decades of research at the ICR, helps delay progression in patients with PTEN-deficient disease – an aggressive form with poor outcomes. Read more ⤵️ www.icr.ac.uk/about-us/icr...

icr.ac.uk

ICR welcomes FDA approval of capivasertib for advanced prostate cancer

110

The Institute of Cancer Research @icr.ac.uk · 11/06/2026

He will also highlight the growing importance of computational approaches and machine learning/AI in areas such as target identification, druggability analysis (e.g. using canSAR), and hit discovery.

000

The Institute of Cancer Research @icr.ac.uk · 11/06/2026

Professor Workman will share his insights on the incredible progress in discovering new precision cancer medicines, and how disruptive technologies are accelerating this progress. This includes advances in PROTACs, molecular glues and the critical role of biomarkers in patient selection.

100

The Institute of Cancer Research @icr.ac.uk · 11/06/2026

🎤 We’re delighted that ICR's Professor Paul Workman is speaking on a panel today at The Galien Foundation Forum at the @sciencemuseum.org.uk where this year’s focus is Future Health Disrupted: From Discovery to Delivery.

120

The Institute of Cancer Research @icr.ac.uk · 09/06/2026

🎙️ICR's Professor Kevin Harrington spoke to Naga Munchetty and Chris Smith on @bbc5live.bsky.social He spoke about how the early discoveries were made that viruses could infect tumours, and how this has led to modern, genetically engineered viruses to treat cancer - called oncolytic virotherapy.

110

The Institute of Cancer Research @icr.ac.uk · 08/06/2026

Making clinical trials more inclusive isn’t just about fairness; it’s about better science. By widening access and considering underserved groups from the outset, researchers can build stronger evidence and help ensure that new cancer treatments work for everyone who needs them.

110

The Institute of Cancer Research @icr.ac.uk · 08/06/2026

Only about 10% of cancer patients take part in clinical trials, and this new study explains why. Eligibility criteria meant to protect participants can also limit inclusion, reducing the number of people who benefit from innovation and producing evidence that may not reflect real-world populations

100

The Institute of Cancer Research @icr.ac.uk · 08/06/2026

UK research shows cancer trials may be unintentionally excluding some of the patients who could benefit most. From explicit criteria like HIV status to less visible barriers like language, access isn’t always equal. Rethinking trial design is key to making research more inclusive and effective.

131

The Institute of Cancer Research @icr.ac.uk · 31/05/2026

New findings from the OrigAMI-4, a study led by Professor Kevin Harrington in advanced head and neck cancer are presented today at #ASCO2026 ⤵️ www.asco.org/abstracts-pr...

010

The Institute of Cancer Research @icr.ac.uk · 30/05/2026

At #ASCO2026 in Chicago, results are shared from Professor Robin Jones's study which explores a new drug for advanced GIST and how patients respond.

010

The Institute of Cancer Research @icr.ac.uk · 30/05/2026

Also this morning at #ASCO2026, Professor James Larkin is presenting his findings from the RAMPART trial, a phase 3 study comparing durvalumab monotherapy with active monitoring after #KidneyCancer surgery ⬇️ www.asco.org/abstracts-pr...

010

The Institute of Cancer Research @icr.ac.uk · 30/05/2026

We're delighted to have researchers from the ICR and The Royal Marsden participating in #ASCO2026 in Chicago. First up today, @prof-nick-james.bsky.social shares findings from the RAD-IO trial, a multi-stage study in #BladderCancer.

010

The Institute of Cancer Research @icr.ac.uk · 21/05/2026

The FAST-Forward trial followed 4,000+ patients for 10 years and confirms that five treatments can deliver the same cancer control—with fewer hospital visits. A major step towards more accessible, efficient cancer care. More from us here ⤵️

icr.ac.uk

One week radiotherapy course shown to be safe and effective in the long term for early stage breast cancer

002

The Institute of Cancer Research @icr.ac.uk · 21/05/2026

🚨 New results published recently in @thelancetoncol.bsky.social show one-week radiotherapy is as safe and effective as the traditional three-week course for early-stage breast cancer.

102

The Institute of Cancer Research @icr.ac.uk · 18/05/2026

We have three more events this week across both of our sites, in Sutton and Chelsea. 🎟️There are still some tickets left to hear from ICR scientists in Sutton tomorrow and on Wednesday. Book them now before they go! pintofscience.co.uk/organisation... #Pint26 #Pint26

pintofscience.co.uk

The Institute of Cancer Research

010

The Institute of Cancer Research @icr.ac.uk · 18/05/2026

🚨@pintofscience.uk begins today! We’re kicking off our Pint of Science events in the Prince Albert pub in Battersea. 🧬 Tonight’s sold-out event features ICR scientists @ioannastefani.bsky.social and Jessica Beecroft. #Pint26

131

The Institute of Cancer Research @icr.ac.uk · 15/05/2026

Find out more about our clinical trials here www.icr.ac.uk/research-and...

000

The Institute of Cancer Research @icr.ac.uk · 15/05/2026

Are you attending the annual @estroradiotherapy.bsky.social congress this weekend? Researchers are presenting 8 different trials managed by the ICR’s Clinical Trials and Statistics Unit. ICR's Professor @profemmahall.bsky.social shares her thoughts ahead of the event ⬇️ #ESTRO26

112

The Institute of Cancer Research @icr.ac.uk · 14/05/2026

The ICR and @breastcancernow.bsky.social aim to change that, bringing researchers together to unpick the biology of lobular disease and identify new, targeted treatment strategies.

111

The Institute of Cancer Research @icr.ac.uk · 14/05/2026

🧬 Lobular #BreastCancer behaves differently from other breast cancers especially once it spreads yet treatment options are still limited.

100

The Institute of Cancer Research @icr.ac.uk · 12/05/2026

ICR researchers have, for the first time, revealed the structure and behaviour of active CDK11, a key protein driving the growth of multiple cancer types and uncovered a new mechanism regulating its activity. More from us here ⤵️

icr.ac.uk

New understanding of enzyme regulating gene expression could inform future cancer therapies

052

The Institute of Cancer Research @icr.ac.uk · 12/05/2026

📢 New research details how an important cellular enzyme is controlled, uncovering new insights into the fundamental biological processes controlling gene expression.

142

Reposted by The Institute of Cancer Research

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 06/05/2026

If you are interested in PARP inhibitors and history, this might be of interest to you. www.nature.com/articles/s41.... An attempt to cover the work of thousands and their immense contributions to the development of a targeted approach to treating cancers.

nature.com

Two decades of PARP inhibitor synthetic lethality in cancer - Nature

The past two decades of PARP inhibitor synthetic lethality in cancer is explored.

01510

Reposted by The Institute of Cancer Research

ICR-CTSU @icr-ctsu.bsky.social · 07/05/2026

A new trial design framework for incorporating patient-reported outcomes into dose-optimisation trials "PRO-ADD (Patient-Reported Outcomes Aided Dose-optimisation Design)" is now published in Statistical Methods in Medical Research: journals.sagepub.com/doi/full/10....

journals.sagepub.com

PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection - Emily Alger, Sumithra J Mandrekar, Jun Yin, Christina...

Advances in oncology drug development are driving the emergence of novel therapies, challenging traditional dose-efficacy assumptions in dose-finding oncology t...

121